<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622826</url>
  </required_header>
  <id_info>
    <org_study_id>ATNONordOvest</org_study_id>
    <nct_id>NCT04622826</nct_id>
  </id_info>
  <brief_title>plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients</brief_title>
  <official_title>Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda USL Toscana Nord Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda USL Toscana Nord Ovest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma&#xD;
      infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms&#xD;
      within seven days from the beginning of symptoms.&#xD;
&#xD;
      Efficacy is evaluated by the number of patients who will improve their clinical condition and&#xD;
      will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma&#xD;
      infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ITU admission</measure>
    <time_frame>up to 30 days</time_frame>
    <description>number of patients admitted to ITU after immune plasma transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>administration of O2</measure>
    <time_frame>up to 30 days</time_frame>
    <description>O2 support will be monitored and reported in its various modes of administration (e.g. nasal cannula, high flow nasal cannula, noninvasive ventilation, mechanical ventilation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>up to 90 days</time_frame>
    <description>number of subject deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>immune plasma infusion adverse reaction</measure>
    <time_frame>in the first 24-48 hours</time_frame>
    <description>number of participants with treatment-related adverse events as assessed by CTCAE v4.0&quot;</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>sequential immune plasma infused patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immune covid 19 plasma infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>immune plasma</intervention_name>
    <description>immune covid 19 plasma infusion</description>
    <arm_group_label>sequential immune plasma infused patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years&#xD;
&#xD;
          -  hospitalized patients with positive covid-19 swab with respiratory symptoms and CT&#xD;
             confirmation of covid-19 chest disease admitted to non ITU recovery area.&#xD;
&#xD;
          -  informed consent for plasma infusion&#xD;
&#xD;
          -  informed consent to blood samples storing for future studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding female patient or planning for a pregnancy in the period of&#xD;
             the study&#xD;
&#xD;
               -  immunoglobulin infusion in the last month&#xD;
&#xD;
        contraindication to transfusion or previous adverse reaction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>antonella vincenti</last_name>
    <role>Principal Investigator</role>
    <affiliation>ospedale delle Apuane</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mirko lombardi</last_name>
    <phone>00393478546332</phone>
    <email>mirkolombardi9@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>antonella vincenti</last_name>
    <phone>003905854931</phone>
    <email>antonella.vincenti@uslnordovest.toscana.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale delle Apuane</name>
      <address>
        <city>Massa</city>
        <state>Toscana</state>
        <zip>54033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mirko lombardi</last_name>
      <phone>+393478546332</phone>
      <email>mirkolombardi9@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>antonella vincenti</last_name>
      <phone>003905854931</phone>
      <email>antonella.vincenti@uslnordovest.toscana.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonella Vincenti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 7, 2020</last_update_submitted>
  <last_update_submitted_qc>November 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda USL Toscana Nord Ovest</investigator_affiliation>
    <investigator_full_name>mirko lombardi</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <keyword>covid-19 pneumonia</keyword>
  <keyword>convalescent plasma</keyword>
  <keyword>hyperimmune plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

